Hatfield, England (ots/PRNewswire) - PRESS RELEASE FOR EU MEDIA ONLY: NOT FOR SWISS/U.S. JOURNALISTS
New Eisai office will support breast cancer treatment Halaven(R)(eribulin)
and first-in-class epilepsy treatment Fycompa(R)(perampanel)
Eisai today announces the official opening of a new office in Melbourne, Australia, which will further expand the company's geographical presence and increase patient reach. The Melbourne office will provide leading global research and development-based pharmaceutical company, Eisai, with an important platform from which its portfolio of novel oncology and epilepsy products will be marketed.
The opening demonstrates Eisai's continuing commitment to improve access to innovative medicines in emerging economies and developing countries, as set out in the company's mid-term strategic plan.
"The launch of the new Eisai office recognises that Australia has an important and distinctive healthcare system. We are delighted to broaden the reach of our innovative oncology and epilepsy products to benefit patients and their families in this key global market," commented Gary Hendler, President & CEO, Eisai EMEA.
The expansion into Australia underscores Eisai's human health care (hhc) mission, the company's commitment to innovative solutions in disease prevention, cure and care for the health and wellbeing of people worldwide.
The first two products to be supported by the new office will be novel breast cancer treatment Halaven(R) (eribulin) and first-in-class epilepsy treatment Fycompa(R) (perampanel).
"We believe Halaven in breast cancer and Fycompa in epilepsy will prove valuable treatment options for clinicians managing these conditions in Australia. While these two products will be our initial focus, Eisai also has an exciting pipeline in oncology, neurology, and the vascular and gastrointestinal fields," commented Dr John Bower PhD, Market Access and Medical Director, Eisai Australia.
Breast cancer is the most common cancer diagnosed in Australian women with one in eight women likely to be diagnosed by the age of 85.[1]
See the rest here:
Eisai Continues Global Expansion with New Office in Melbourne, Australia